title: Changes in evaluation of the pepsinogen test result following Helicobacter pylori eradication therapy in Japan.
abstract: OBJECTIVE
  The pepsinogen (PG) test result is used in Japan for screening for gastric cancer. In this study, we investigated the changes in evaluation of the PG test result following H. pylori eradication.
  
  
  METHODS
  The subjects were 120 consecutive H. pylori-positive patients with upper gastrointestinal symptoms. Subjects underwent endoscopy prior to, and at 2 months after the eradication therapy, at which time blood was taken for determination of changes in PG levels.
  
  
  RESULTS
  The overall eradication rate was 79.3% (per protocol). Following eradication therapy, the evaluation of PG test result converted from positive to negative in 80.4% (37/46) of cases of successful eradication, and in 0% (0/6) of cases of eradication failure.
  
  
  CONCLUSIONS
  These results suggest that the evaluation of PG test result should be used after the definitive confirmation of the success or failure of H. pylori eradication therapy.
authors.affiliation: Endoscopy Center, Tokyo Medical University Hospital, 671 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. t-kawai@tokyo-med.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Kawai
authors.forename: K
authors.initials: K
authors.lastname: Miki
authors.forename: M
authors.initials: M
authors.lastname: Ichinose
authors.forename: Y
authors.initials: Y
authors.lastname: Kenji
authors.forename: I
authors.initials: I
authors.lastname: Miyazaki
authors.forename: K
authors.initials: K
authors.lastname: Kawakami
authors.forename: M
authors.initials: M
authors.lastname: Kataoka
authors.forename: T
authors.initials: T
authors.lastname: Yamagishi
authors.forename: A
authors.initials: A
authors.lastname: Sofuni
authors.forename: T
authors.initials: T
authors.lastname: Itoi
authors.forename: F
authors.initials: F
authors.lastname: Moriyasu
authors.forename: Y
authors.initials: Y
authors.lastname: Takagi
authors.forename: T
authors.initials: T
authors.lastname: Aoki
authors.forename: J
authors.initials: J
authors.lastname: Matsubayashi
authors.forename: K
authors.initials: K
authors.lastname: Mukai
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D010435:Pepsinogens / Q000097:blood*; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D010435:Pepsinogens